(S) -Doxazosin

• Description:

  (S) -Doxazosin is a long-acting selective α1-adrenoceptor antagonist. (S) -Doxazosin exhibits antihypertensive activity through lowering total perioheral resistance by selective postsynaptic α1-blockade. (S) -Doxazosin reduces blood pressure in dog model with experimentally induced renal hypertension. (S) -Doxazosin can alleviate bladder outflow obstruction. (S) -Doxazosin can also be studied in mental health disorder-related research[1][2][3].

• Product Name Alternative:

  (S) -UK 33274

• UNSPSC:

  12352005

• Target:

  Adrenergic Receptor

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease; Cardiovascular Disease

• Smiles:

  O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)[C@H]4OC5=CC=CC=C5OC4

• Molecular Formula:

  C23H25N5O5

• Molecular Weight:

  451.48

• References & Citations:

  [1]Fulton, B., et al., (1995) . Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs, 49 (2), 295-320. |[2]Young, R. A., & Brogden, R. N. (1988) . Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. Drugs, 35 (5), 525-541.|[3]Christie S. Richardson, et al., (2025) . Doxazosin for the treatment of mental health disorders: A scoping review. PLOS Mental Health.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  104874-86-4